Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intranasal Vasopressin Treatment in Children With Autism

Trial Profile

Intranasal Vasopressin Treatment in Children With Autism

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 May 2018

At a glance

  • Drugs Vasopressin (Primary)
  • Indications Pervasive child development disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 20 Sep 2017 Planned initiation date changed from 1 Jul 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top